The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients

Summary

The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and standard of care in hospitalized adult patients diagnosed with COVID-19. This trial will follow the core WHO protocol but has additional efficacy, safety and explorative endpoints.

Conditions

• SARS-CoV Infection
• COVID 19
• Acute Respiratory Distress Syndrome ARDS

Interventions

DRUG

Hydroxychloroquine

Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.

DRUG

Remdesivir

Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.

OTHER

(Standard of Care) SoC

The standard of care will be supplied to all patients not receiving a drug intervention.

Sponsors & Collaborators

• Oslo University Hospital

  lead OTHER

Principal Investigators

• Paul Aukrust, MD, Professor · Oslo University Hospital

• Andreas Barratt-Due, MD, PhD · Oslo University Hospital

• Trine Kåsine, MD · Oslo University Hospital

• Katerina Nezvalova-Henriksen, Pharm D, PhD · Oslo Hospital Pharmacies

• Anne Margarita Dyrhol Riise, MD, Professor · Oslo University Hospital

• Marius Trøseid, MD, PhD · Oslo University Hospital

• Inge Christoffer Olsen, PhD · NorCRIN

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-03-28

Primary Completion

2020-08-31

Completion

2020-11-30

Countries

• Norway

Study Locations